ArticleGene therapy2006
Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Article in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Measles virus for cancer therapy.Current topics in microbiology and immunology · 2009Trial
- Enhancing antitumor immunity through oncolytic viruses: advances in genetic engineering.Discover oncology · 2026Review
- Oncolytic viruses against cancer, promising or delusion?Medical oncology (Northwood, London, England) · 2023Review
- Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.Cancer gene therapy · 2021Review
- Engineering and combining oncolytic measles virus for cancer therapy.Cytokine & growth factor reviews · 2020Review
- Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.Cancers · 2020Review
- Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade.Cancer cell international · 2020Article
- Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.Cancer science · 2018Article
- Review
- Oncolytic virus therapy: A new era of cancer treatment at dawn.Cancer science · 2016Review
- The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein.Viruses · 2016Review
- A Double-Switch Cell Fusion-Inducible Transgene Expression System for Neural Stem Cell-Based Antiglioma Gene Therapy.Stem cells international · 2015Article
- Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.Cancer gene therapy · 2013Article
- Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.BioMed research international · 2013Article
- Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.Journal of cancer research and clinical oncology · 2012Article
- Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.Cancer gene therapy · 2012Article
- MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Rapid and sensitive lentivirus vector-based conditional gene expression assay to monitor and quantify cell fusion activity.PloS one · 2010Article
- TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer.Gene therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using Chou-Talalay median effect analysis, we demonstrated in permanent and short-term cultures of colorectal cancer cells that the expression of measles virus fusogenic membrane glycoproteins (FMGs) in combination with chemotherapy often causes over most of the cytotoxic dose range synergistic cell killing. In this combined treatment, we observed strongly enhanced annexin V binding and caspase-3/7 activity when compared to single-agent treatment. Furthermore, we showed increased expression of heat-shock protein (Hsp)70 and Hsp90alpha, but not of Hsp60. In a subcutaneous HT-29 colorectal xenograft model, we demonstrated that the administration of a replication-defective adenoviral or herpes simplex virus (HSV) amplicon vector (Ad.H/F or HSV.H/F) encoding tumor-restricted FMG in combination with FOLFOX significantly enhanced treatment outcome when compared to treatment with each compound individually. To increase the fraction of tumor cells expressing the FMG, we trans-complemented the Ad.H/F and HSV.H/F vector with the respective oncolytic replication-restricted adenovirus Ad.COXDeltaMK or HSV-1 G47Delta vector. At the end of the observation period (day 100), eight out of 10 animals that received G47Delta, HSV.H/F and FOLFOX were alive and tumor free. Administration of the analogous adenovirus-based regimen resulted in four out of 10 long-term survivors. We demonstrated that the expression of FMG in combination with chemotherapy can significantly enhance treatment outcome, which is further enhanced by combination with trans-complementing oncolytic vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.